Ricerc@Sapienza

Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a very rare CD30-positive ALK-negative T-cell non-Hodgkin lymphoma included as a provisional entity in the 2017 WHO classification of lymphoid neoplasms. BIA-ALCL arises as proliferating cells over the surface of the implant. It is generally an indolent disease if confined within the fibrous capsule. In contrast, mass and/or infiltration beyond the capsule is much more aggressive.

Breast implant-associated anaplastic large cell lymphoma (BI-ALCL) is a rare T-cell lymphoma that arises around breast implants. Most patients manifest with periprosthetic effusion, whereas a subset of patients develops a tumor mass or lymph node involvement (LNI). The aim of this study is to describe the pathologic features of lymph nodes from patients with BI-ALCL and assess the prognostic impact of LNI. Clinical findings and histopathologic features of lymph nodes were assessed in 70 patients with BI-ALCL. LNI was defined by the histologic demonstration of ALCL in lymph nodes.

Breast implant-associated anaplastic large-cell lymphoma (BI-ALCL) is a variant of anaplastic large-cell lymphoma arising within seroma effusion associated to breast implants. BI-ALCL is a rare disease, recently recognized as a new provisional entity by the 2017 revised WHO classification. All BI-ALCLs tested so far showed a "triple negative" genetic profile - negative for ALK, DUSP22, and TP63 rearrangements - and were characterized by mutational and gene expression profiles consistent with aberrant activation of the JAK/STAT pathway.